Want to see TSE:CRDL full AI Analyst Report?
CRDL Stock Chart & Stats
C$2.06
-C$0.08(-4.06%)
At close: 4:00 PM EST
C$2.06
-C$0.08(-4.06%)
Day’s Range― - ―
52-Week RangeC$1.23 - C$2.33
Previous CloseN/A
Volume34.34K
Average Volume (3M)136.50K
Market Cap
C$171.76M
Enterprise ValueC$144.20M
Total Cash (Recent Filing)C$27.67M
Total Debt (Recent Filing)C$116.41K
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Aug 17, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding115,272,240
10 Day Avg. Volume86,077
30 Day Avg. Volume136,495
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)6.37
Price to Sales (P/S)0.00
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$12.08Price Target Upside486.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageA debt-to-equity ratio near 0.005 materially reduces refinancing and solvency risk for a clinical-stage biotech. Structurally, minimal leverage lengthens management's flexibility to fund trials or seek non-debt capital, lowering bankruptcy risk as clinical programs advance.
Focused Clinical-stage PipelineCardiol's clear therapeutic focus on anti-inflammatory and anti-fibrotic cardiovascular assets (CardiolRx and CRD-38) concentrates R&D effort on adjacent indications. That specialization can create durable competitive advantage in a defined niche if clinical efficacy is demonstrated, enabling targeted regulatory and commercial planning.
Narrowing Cash Outflows TrendReported improvement versus prior years indicates management may be reducing burn or reallocating spend. A sustained decline in cash outflows would structurally lower near-term financing needs, reduce dilution risk and provide more runway to reach key clinical milestones without urgent capital raises.
Bears Say
Pre-revenue StatusAbsent commercial revenue, Cardiol must rely on external financing to fund operations and trials. This structural dependency subjects execution to capital-market cycles and elevates dilution and timing risk; sustained lack of revenue limits operating leverage and long-term self-sufficiency.
Sizable Cash BurnPersistent negative operating and free cash flow near -$24M TTM creates an ongoing funding gap. Structurally high burn rates increase the probability of future equity raises, compress investor returns, and limit the firm's ability to expand R&D or commercial capabilities without dilution.
Negative Returns And Equity ErosionDeclining equity and negative ROE indicate ongoing value erosion from losses. Over time this weakens the balance-sheet buffer, heightens vulnerability to adverse clinical outcomes, and raises the likelihood that management must seek dilutive financing to restore capital.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was C$1.23 and its highest was C$2.33 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is C$171.76M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 45 days.
How were Cardiol Therapeutics’s earnings last quarter?
Currently, no data Available
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 115,272,240 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in TSE:CRDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$12.08 (486.49% Upside)
C$12.08 (486.49% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▲ 7.8%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.03%
12-Months-Change
Fundamentals
Return on Equity
-229.16%
Trailing 12-Months
Asset Growth
27.24%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
C$12.08
▲(486.49% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―
Options Prices
Currently, No data available
---